REPLACED BY ART 34 AMDT

## CLAIMS

1. A compound of formula:

$$Y\text{-}(CR_2)_n\text{-}X\text{-}NHJ$$

where:

X is C=O or $CR_2$;

n is an integer of value 1 to 6;

Y is $L(A)_m$- or $R^1R^2CR$- where L is a metal complexing agent,

A is $-CR_2-$ , -CR=CR- , $-C\equiv C-$ , -NRCO- , -CONR- , $-SO_2NR-$ , $-NRSO_2-$ , $-CR_2OCR_2-$ , $-CR_2SCR_2-$ , $-CR_2NRCR_2-$ , a $C_{4-8}$ cycloheteroalkylene group, a $C_{4-8}$ cycloalkylene group, a $C_{5-12}$ arylene group, a $C_{3-12}$ heteroarylene group or a polyalkyleneglycol, polylactic acid or polyglycolic acid moiety;

m is an integer of value 0 to 10;

where one of $R^1$ and $R^2$ is $-NH(B)_pZ^1$ and the other is $-CO(B)_qZ^2$ where

p and q are integers of value 0 to 45, and

each B is independently chosen from Q or an amino acid residue,

where Q is a cyclic peptide;

$Z^1$ and $Z^2$ are protecting groups;

J and each R group are independently chosen from H, $C_{1-4}$ alkyl, $C_{1-4}$ alkenyl, $C_{1-4}$ alkynyl, $C_{1-4}$ alkoxyalkyl or $C_{1-4}$ hydroxyalkyl;

with the provisos that:

(i) the total number of amino acid residues in the $R^1$ and $R^2$ groups does not exceed 45;

(ii) when X is $CR_2$, then Y is $-CRR^1R^2$ and $Z^2$ is a metal complexing agent;

(iii) when Y is $-CRR^1R^2$ then at least one of $R^1$ and $R^2$ bears at least one detectable moiety.

2. The compound of claim 1 where $R^1$ or $R^2$ includes one or more peptide fragments of $\alpha_2$-antiplasmin, fibronectin, beta-casein, tetanus, amyloid, trappin and polyglutamine residues, said peptide fragment containing at least three amino acid residues.

3. The compound of claim 2 where the peptide fragment is from $\alpha_2$-antiplasmin.

4. The compound of claim 3 where the amino acid in the 2-position from the peptide N-terminus is glutamine.

5. The compound of ~~claims 1 to 4~~ Claim 1 where J is H.

6. The compound of claim 5 of formula:

$Y\text{-}(CR_2)_x\text{-}(CH_2)_2CONH_2$ or $Y\text{-}(CR_2)_y\text{-}(CH_2)_4NH_2$

where x is an integer of value 0 to 4, and y is an integer of value 0 to 3.

7. The compound of ~~any one of claims 1 to 6~~ Claim 1 where Y is $-CRR^1R^2$.

8. The compound of ~~any one of claims 1 to 7~~ Claim 1 where at least one of $Z^1$ and $Z^2$ is a metal complexing agent.

9. The compound of claim 8 where $Z^2$ is a metal complexing agent and $Z^1$ is not a metal complexing agent.

10. A metal complex of the compounds of claim 8 ~~or claim 9~~.

11. The metal complex of claim 10 where the metal is a radiometal.

12. The radiometal complex of claim 11 where the radiometal is $^{99m}Tc$.

13. A preparation for human administration comprising the compound of ~~any one of claims 1 to 12~~.

14. A kit comprising ~~the compound~~ of any one of claims 1 to 9 useful in the preparation of the metal complexes of any one of claims 10 to 12.

15. Use for the diagnosis of sites of thrombosis or embolism of a compound of formula:

$$Y\text{-}(CR_2)_n\text{-}X\text{-}NHJ$$

where:

X is C=O or $CR_2$;

n is an integer of value 1 to 6;

Y is $L(A)_m$- or $R^1R^2CR$- where L is a metal complexing agent,

A is $-CR_2$- , -CR=CR- , -C≡C- , -NRCO- , -CONR- , $-SO_2NR$- , $-NRSO_2$- , $-CR_2OCR_2$- , $-CR_2SCR_2$- , $-CR_2NRCR_2$- ; a $C_{4-8}$ cycloheteroalkylene group, a $C_{4-8}$ cycloalkylene group, a $C_{5-12}$ arylene group, a $C_{3-12}$ heteroarylene group or a polyalkyleneglycol, polylactic acid or polyglycolic acid moiety;

m is an integer of value 0 to 10;

where one of $R^1$ and $R^2$ is $-NH(B)_pZ^1$ and the other is $-CO(B)_qZ^2$ where

p and q are integers of value 0 to 45, and

each B is independently chosen from Q or an amino acid residue,

where Q is a cyclic peptide;

$Z^1$ and $Z^2$ are protecting groups;

J and each R group are independently chosen from H, $C_{1-4}$ alkyl, $C_{1-4}$ alkenyl, $C_{1-4}$ alkynyl, $C_{1-4}$ alkoxyalkyl or $C_{1-4}$ hydroxyalkyl;

with the provisos that:

(i) the total number of amino acid residues in the $R^1$ and $R^2$ groups does not exceed 45;

(ii) when X is $CR_2$, then Y is $-CRR^1R^2$;

(iii) when Y is $-CRR^1R^2$ then at least one of $R^1$ and $R^2$ bears at least one detectable moiety.

16. Use for the diagnosis of sites of thrombosis or embolism of a radiometal complex of the compound defined in claim 13, wherein at least one of $Z^1$ and $Z^2$ is a metal complexing agent.

17. A peptide fragment of $\alpha_2$-antiplasmin, fibronectin, beta-casein, tetanus, amyloid, trappin or polyglutamine, said peptide fragment containing 3 – 45 amino acid residues and carrying a terminal metal complexing agent.

18. The peptide fragment of claim 17, wherein the metal complexing agent is at the carboxy terminus.

19. A metal complex of the peptide fragment of claim 17 ~~or claim 18~~.